# Phase 1 Dose Escalation of ArtemiCoffee

> **NCT04805333** · PHASE1 · COMPLETED · sponsor: **Frederick R. Ueland, M.D.** · enrollment: 13 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Artemisia annua 450mg
- **DRUG:** Artemisia annua 900mg
- **DRUG:** Artemisia annua 1350mg
- **DRUG:** Artemisia annua 1800mg
- **DRUG:** Artemisia annua - recommended phase II dose

## Key facts

- **NCT ID:** NCT04805333
- **Lead sponsor:** Frederick R. Ueland, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-26
- **Primary completion:** 2025-02-04
- **Final completion:** 2025-02-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04805333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04805333, "Phase 1 Dose Escalation of ArtemiCoffee". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04805333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*